Lower numbers = closer to natural. Higher numbers = more enhanced.
Why this rating?
RAD-150 is marketed as the benzoate ester (TLB-150) of RAD-140 (testolone), i.e. a prodrug intended to release RAD-140 more slowly for longer-acting exposure. There is essentially no published human or preclinical data on RAD-150 itself; its presumed pharmacology is inherited from RAD-140, a genuinely suppressive SARM that is prohibited by WADA and requires PCT. Rated 6 to match RAD-140 on the assumption it delivers the same active molecule, but this rests on the parent compound, not on data for RAD-150 itself. The uncertainty is real.
Overview
A grey-market "SARM" sold as RAD-150 or TLB-150 and described by vendors as the benzoate ester of RAD-140 (testolone), an ester prodrug intended to be longer-acting. Once cleaved, it is presumed to act as RAD-140, a nonsteroidal selective androgen receptor modulator. Important caveat: there is essentially no peer-reviewed literature on RAD-150 specifically, so almost everything below is extrapolated from its parent compound RAD-140.
Important Warnings
- •Essentially no published human or preclinical data exists on RAD-150 itself. Claims are extrapolated from RAD-140
- •Not approved for human use; grey-market products are frequently mislabelled, underdosed, overdosed, or spiked
- •Presumed to be genuinely suppressive (via RAD-140), treat as a hormonal cycle with bloodwork and PCT
- •SARM hair loss is androgen-receptor-mediated. Finasteride/dutasteride will NOT prevent it
Purpose & Use Cases
Lean Mass / Strength (Presumed)
Marketed for the same muscle and strength goals as RAD-140, on the basis that it delivers RAD-140 as the active molecule.
Longer-Acting Dosing (Claimed)
The ester is promoted for more stable levels / less frequent dosing than RAD-140, a vendor claim, not established by data.
Benefits
- Presumed to deliver RAD-140's lean-mass and strength effects once de-esterified
- Does not aromatize (like RAD-140), no estrogenic water retention from the SARM itself
- Oral, no injection
- Claimed longer/steadier exposure than RAD-140 (unverified)
Good to Know
It is a prodrug of RAD-140, with far less data
RAD-150 (TLB-150) is sold as the benzoate ester of RAD-140. The rationale is a slower-releasing, longer-acting version of testolone. But RAD-140 itself only has one published human trial (in breast-cancer patients), and RAD-150 has essentially none, so it is a research chemical layered on top of a research chemical.
"Ester" does not mean "safer"
A longer-acting prodrug can mean longer suppression, not milder effects. Suppression, lipid changes and possible liver strain from RAD-140 all carry over. Run bloodwork and a proper PCT.
Milligrams are not comparable to RAD-140
Because part of the molecule's weight is the benzoate ester, a labelled milligram of RAD-150 does not equal a milligram of RAD-140 of active drug. Combined with grey-market mislabelling, actual dosing is genuinely uncertain.
Dosage Guidelines
| Experience Level | Dosage Range |
|---|---|
| Beginner | 10 – 10 mg/day |
| Intermediate | 10 – 15 mg/day |
| Advanced | 15 – 20 mg/day |
There is NO clinical dosing data for RAD-150. These figures are drawn from multiple grey-market vendor listings, which converge on ~10-20 mg/day (beginner ~10 mg, advanced up to ~20 mg) and simply mirror common RAD-140 label/community doses; none of it is validated by any study. Because RAD-150 is an ester, the labelled milligrams are not equivalent milligram-for-milligram to RAD-140 (part of the mass is the inert benzoate group). Vendors do not appear to adjust dosing for this, so the true active-RAD-140 dose delivered per label-mg is likely lower than it looks. Grey-market SARM products are frequently mislabelled or spiked; treat any product as unverified.
Not established for RAD-150 in any published pharmacokinetic study; grey-market vendor material variously claims ~48 hours or "roughly 2x RAD-140" (RAD-140 itself has a reported half-life of ~45-60 hours). These vendor figures are inconsistent with each other and unverified.
Side Effects
Testosterone Suppression
very commonRAD-140 is a genuinely suppressive SARM; RAD-150 is expected to suppress the HPTA similarly (or longer, if the ester truly extends exposure).
Treat as a hormonal cycle: bloodwork and a proper SERM PCT (enclomiphene or tamoxifen).
Lipid Changes (HDL Down)
commonOral androgens/SARMs including RAD-140 lower HDL and can raise LDL.
Lipid panel before/during; omega-3 and citrus bergamot; cardio.
Liver Strain
uncommonRAD-140 has case reports of drug-induced liver injury; RAD-150 carries the same presumed risk.
TUDCA; stop and seek care if enzymes climb sharply or jaundice appears.
Product Quality / Unknown Identity
commonRAD-150 is an unstudied grey-market chemical; purity, actual content and even true identity are uncertain.
Third-party testing where possible; recognise the data gap.
General Mitigation Strategies
Because RAD-150 has no safety data of its own, apply the precautions established for RAD-140: get bloodwork, run a proper SERM PCT, monitor lipids and liver enzymes, and keep cycles short. Do not assume the "ester" makes it milder, if anything a longer-acting prodrug can prolong suppression.
Post Cycle Therapy (PCT)
Treat as a suppressive SARM cycle. SERM PCT with enclomiphene (12.5-25 mg/day) or tamoxifen (20/20/10/10) for ~4 weeks. If the ester genuinely prolongs exposure, delay PCT until the compound has cleared. Confirm recovery with bloodwork.
How It Works
RAD-150 is presented as an esterified prodrug that is hydrolysed to RAD-140. RAD-140 itself is a nonsteroidal, tissue-selective (partial/mixed) agonist of the androgen receptor (binding affinity Ki ~7 nM, tighter than testosterone), acting as a full agonist in muscle and bone. The benzoate ester is claimed to slow release and prolong exposure, analogous to how esterified steroids extend a hormone's duration, but the ester's actual pharmacokinetics in humans have not been published.
Hormonal & Androgenic Profile
Presumed to mirror RAD-140 (highly muscle-selective in preclinical assays), but no ratio has been measured for RAD-150 itself.
Does not aromatize (inherited from RAD-140), no AI needed for the SARM itself. Manage estrogen only if an aromatizing base is stacked.
Not a 5α-reductase substrate: finasteride/dutasteride do nothing for SARM-related shedding, which is direct androgen-receptor activation at the follicle (same as RAD-140).
Expected to lower HDL like RAD-140; no aromatization means no estrogenic water retention. Monitor lipids.
Fundamentals
Reference on the practices relevant to RAD-150: how they are done and where they go wrong. Not a recommendation to use it.
Legal Status
Unapproved grey-market SARM; not approved for human use.
Legal status varies by country and changes over time. This is a general summary, not legal advice.
WADA Status
SARMs are prohibited at all times under S1.2 (Other Anabolic Agents), and RAD-140 is explicitly listed. As an ester/prodrug of RAD-140, RAD-150 is captured by the same prohibition (WADA bans substances with similar chemical structure or biological effect).